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BackgroundAlthough practice guidelines recommend outpatient care for selected,
haemodynamically stable patients with pulmonary embolism, most treatment is
presently inpatient based. We aimed to assess non-inferiority of outpatient care
compared with inpatient care. Methods We undertook an open-label, randomised
non-inferiority trial at 19 emergency departments in Switzerland, France, Belgium,
and the USA. We randomly assigned patients with acute, symptomatic pulmonary
embolism and a low risk of death (pulmonary embolism severity index risk classes I
or II) with a computer-generated randomisation sequence (blocks of 2–4) in a 1:1
ratio to initial outpatient (ie, discharged from hospital ≤24 h after randomisation) or
inpatient treatment with subcutaneous enoxaparin (≥5 days) followed by oral
anticoagulation (≥90 days). The primary outcome was symptomatic, recurrent venous
thromboembolism within 90 days; safety outcomes included major bleeding within 14
or 90 days and mortality within 90 days. We used a non-inferiority margin of 4% for a
difference between inpatient and outpatient groups. We included all enrolled patients
in the primary analysis, excluding those lost to follow-up. This trial is registered with
ClinicalTrials.gov, number NCT00425542. Findings Between February, 2007, and
June, 2010, we enrolled 344 eligible patients. In the primary analysis, one (0·6%) of
171 outpatients developed recurrent venous thromboembolism within 90 days
compared with none of 168 inpatients (95% upper confidence limit [UCL] 2·7%;
p=0·011). Only one (0·6%) patient in each treatment group died within 90 days (95%
UCL 2·1%; p=0·005), and two (1·2%) of 171 outpatients and no inpatients had major
bleeding within 14 days (95% UCL 3·6%; p=0·031). By 90 days, three (1·8%)
outpatients but no inpatients had developed major bleeding (95% UCL 4·5%;
p=0·086). Mean length of stay was 0·5 days (SD 1·0) for outpatients and 3·9 days (SD
3·1) for inpatients. Interpretation In selected low-risk patients with pulmonary
embolism, outpatient care can safely and effectively be used in place of inpatient
care. Funding Swiss National Science Foundation, Programme Hospitalier de
Recherche Clinique, and the US National Heart, Lung, and Blood Institute. Sanofi-
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